Evidence Explorer · MS-N224 · Supportive nutrition and feeding routes · Appraised November 3, 2026
Home parenteral nutrition may be considered for carefully selected people with inoperable malignant bowel obstruction, but available survival and quality-of-life evidence is observational and very uncertain. Treatment burden and goals of care are central.
Evidence at a glance
Benefit signal: Possible support for selected patients; unproven survival or quality-of-life benefit
Certainty: Very low
Risk context: Central-line infection, thrombosis, fluid/metabolic complications and substantial treatment burden
What was studied
A 2018 Cochrane review included 13 observational studies with 721 participants. Median survival estimates ranged from 15 to 155 days; quality-of-life findings were equivocal. Among extractable data, 32 of 260 people (12%) developed a catheter infection or were hospitalized for a parenteral-nutrition complication.
MASCC guidance advises offering nutrition only when benefits are expected to outweigh risks, with individualized discussion of prognosis, performance status, goals and practical support.
What this evidence cannot establish
There were no reliable randomized comparisons. Apparent survival in cohorts is strongly affected by selecting patients well enough to receive home treatment.
Parenteral nutrition does not relieve the mechanical obstruction or treat the cancer. It may prolong burdens as well as life, depending on the situation.
Practical safety context
A central venous catheter and trained home support are required. Infection, thrombosis, electrolyte and glucose abnormalities, fluid overload and liver complications require monitoring.
At end of life, routine parenteral nutrition can worsen edema, secretions or treatment burden without improving comfort. Decisions should be revisited as goals and condition change.
Questions for the care team
- What outcome are we hoping for—time at home, treatment continuation, strength or comfort?
- What is the best estimate of prognosis and performance trajectory?
- Who will manage the catheter, laboratory monitoring, complications and stopping plan?
Sources
- Cochrane review of home parenteral nutrition (PMID 30095168)
- MASCC malignant bowel-obstruction recommendations (PMID 35274188)
Sources and publication status checked November 3, 2026. Guidance and observational evidence were not counted as randomized trials.
For education, not personal medical advice. Nutrition and supplement decisions during cancer care should be individualized with the oncology and dietetics teams.
